19A172

An Evaluation of Polypharmacy and Adverse Drug Events in Older Adults with Rheumatic Disease

Author(s)

Niamh Mooney, Evelyn Hannon, Mary Buckley, Grainne Murphy

Department(s)/Institutions

Department of Medicine, University College Cork, Cork, Ireland Department of Rheumatology, Cork University Hospital, Cork, Ireland

Introduction

Polypharmacy among older adults is a well-documented problem. The practice has been associated with potentially inappropriate medications (PIMs), adverse drug events (ADEs) and hospitalization. The Screening Tool of Older Persons’ Medications (STOPP) criteria has never been used to evaluate polypharmacy in a rheumatic disease population.

Aims/Background

This retrospective cohort study aims to evaluate polypharmacy, ADEs and anticholinergic burden in the ≥65 population with rheumatic disease.

Method

All patients ≥65 with a diagnosed rheumatic disease were included in this study. Patients’ medication lists, specific rheumatic disease, laboratory findings and associated comorbidities were obtained from their medical charts at rheumatology outpatient clinics. The data was screened for PIMs using the STOPP criteria and probable ADEs using the WHO-UMC criteria. Anticholinergic burden was determined using the ACB calculator. Polypharmacy in this project was defined ≥4 regular prescription medications.

Results

70 patients were studied. The prevalence of polypharmacy was 94%. The median (IQR) number of regular prescription medications was 7 (2-16). PIMs were recorded in 43 patients (61%). Increasing numbers of medications was a significant risk factor for PIMs (p=0.0027). ADEs were detected in 18 patients (26%). The ADE detection rate in PIM positive patients was 35% (15/43) and 11% (3/27) in PIM negative patients. A patient who was PIM positive had a statistically significant risk of having an ADE (p=0.047). Of the ADEs detected, 73% were due to a STOPP PIM.
Increasing numbers of medications was a significant risk factor for an increased anticholinergic burden (p=0.017). An anticholinergic burden of ≥3 was a statistically significant risk factor for falls (p=0.025), however it was not a statistically significant risk factor for cognitive decline (p=0.073).

Conclusions

There is a high prevalence of polypharmacy in older adults with rheumatic disease. Increasing numbers of medications is statistically associated with increased numbers of PIMs, ADEs and increased anticholinergic burden. An anticholinergic burden of ≥3 is associated with an increased risk of falls.
The STOPP criteria offer an effective method of detecting the presence of and reducing inappropriate prescribing. Evaluation of polypharmacy using the STOPP criteria may lead to a reduction of ADEs in older adults with rheumatic disease.